NO20090202L - Prolylhydroksylaseinhibitorer - Google Patents

Prolylhydroksylaseinhibitorer

Info

Publication number
NO20090202L
NO20090202L NO20090202A NO20090202A NO20090202L NO 20090202 L NO20090202 L NO 20090202L NO 20090202 A NO20090202 A NO 20090202A NO 20090202 A NO20090202 A NO 20090202A NO 20090202 L NO20090202 L NO 20090202L
Authority
NO
Norway
Prior art keywords
formula
prolylhydroksylaseinhibitorer
anemia
hiv
antagonists
Prior art date
Application number
NO20090202A
Other languages
English (en)
Other versions
NO342019B1 (no
Inventor
Kevin J Duffy
Antony N Shaw
Kenneth Wiggall
Duke M Fitch
Jian Jin
Ronggang Liu
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20090202L publication Critical patent/NO20090202L/no
Publication of NO342019B1 publication Critical patent/NO342019B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Oppfinnelsen beskrevet heri angår visse pyrimidintrion-N-substituerte glysinderivater med formel (I), formel (I) som er antagonister av HIV-prolylhydroksylaser og er anvendelige for behandling av sykdommer som har fordel av inhiberingen av dette enzymet, hvor anemi er et eksempel.
NO20090202A 2006-06-23 2009-01-13 Prolylhydroksylase inhibitorer NO342019B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80560206P 2006-06-23 2006-06-23
PCT/US2007/071854 WO2007150011A2 (en) 2006-06-23 2007-06-22 Prolyl hydroxylase inhibitors

Publications (2)

Publication Number Publication Date
NO20090202L true NO20090202L (no) 2009-03-23
NO342019B1 NO342019B1 (no) 2018-03-12

Family

ID=38834409

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090202A NO342019B1 (no) 2006-06-23 2009-01-13 Prolylhydroksylase inhibitorer

Country Status (31)

Country Link
US (10) US8324208B2 (no)
EP (1) EP2037922B9 (no)
JP (1) JP5203361B2 (no)
KR (1) KR101411816B1 (no)
CN (1) CN101505752B (no)
AR (1) AR061570A1 (no)
AU (1) AU2007260837B2 (no)
BR (1) BRPI0713446B8 (no)
CA (1) CA2655491C (no)
CR (1) CR10534A (no)
DK (1) DK2037922T3 (no)
EA (1) EA018220B1 (no)
ES (1) ES2453100T3 (no)
HK (1) HK1130671A1 (no)
HR (1) HRP20140306T1 (no)
IL (1) IL196070A (no)
JO (1) JO2934B1 (no)
MA (1) MA30526B1 (no)
MX (1) MX2009000165A (no)
MY (1) MY149861A (no)
NO (1) NO342019B1 (no)
NZ (1) NZ573698A (no)
PE (1) PE20080209A1 (no)
PL (1) PL2037922T3 (no)
PT (1) PT2037922E (no)
SG (1) SG174775A1 (no)
SI (1) SI2037922T1 (no)
TW (1) TWI394747B (no)
UA (1) UA100225C2 (no)
WO (1) WO2007150011A2 (no)
ZA (1) ZA200810602B (no)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006105237A2 (en) * 2005-03-29 2006-10-05 The University Of Maryland, Baltimore Inhibitors for extracellular signal-regulated kinase docking domains and uses therefor
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
PE20080209A1 (es) 2006-06-23 2008-05-15 Smithkline Beecham Corp Derivados de glicina como inhibidores de prolil hidroxilasa
SI2044005T1 (sl) 2006-06-26 2011-01-31 Warner Chilcott Co Llc Inhibitorji prolilhidroksilaze in postopki uporabe
GB0622472D0 (en) * 2006-11-10 2006-12-20 Addex Pharmaceuticals Sa Novel heterocyclic derivatives
AU2007334321B2 (en) 2006-12-18 2012-03-08 Amgen Inc. Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
EP2111399A2 (en) 2006-12-18 2009-10-28 Amgen Inc. Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
EP2155680B1 (en) 2007-04-18 2013-12-04 Amgen, Inc Indanone derivatives that inhibit prolyl hydroxylase
US8048894B2 (en) 2007-04-18 2011-11-01 Amgen Inc. Quinolones and azaquinolones that inhibit prolyl hydroxylase
WO2008137060A1 (en) 2007-05-04 2008-11-13 Amgen Inc. Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
WO2008137084A2 (en) 2007-05-04 2008-11-13 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
AR070027A1 (es) 2007-09-17 2010-03-10 Abbott Lab Agentes anti-infecciosos contra el virus hcv
EP2252619B1 (en) 2008-01-11 2013-10-09 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
US8324405B2 (en) 2008-02-05 2012-12-04 Fibrogen, Inc. Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors
AU2009225869B2 (en) 2008-03-18 2014-01-23 Merck Sharp & Dohme Llc Substituted 4-hydroxypyrimidine-5-carboxamides
CN105622580B (zh) 2008-04-28 2019-06-21 詹森药业有限公司 作为脯氨酰羟化酶抑制剂的苯并咪唑
GB0809262D0 (en) 2008-05-21 2008-06-25 Isis Innovation Assay
JP2011525924A (ja) * 2008-06-25 2011-09-29 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー プロリルヒドロキシラーゼ阻害剤
CN102264740B (zh) 2008-08-20 2014-10-15 菲布罗根有限公司 一种吡咯[1,2-b]哒嗪衍生物及其作为hif调节剂的用途
JP2012500850A (ja) * 2008-08-25 2012-01-12 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー プロリルヒドロキシラーゼ阻害剤
AU2009314155B2 (en) 2008-11-14 2015-10-08 Fibrogen, Inc. Thiochromene derivatives as HIF hydroxylase inhibitors
EP2396316B1 (en) 2009-02-10 2015-07-01 Janssen Pharmaceutica, N.V. Quinazolinones as prolyl hydroxylase inhibitors
US8841447B2 (en) 2009-03-26 2014-09-23 Mapi Pharma Ltd. Process for the preparation of alogliptin
CA2798183C (en) * 2009-05-05 2018-04-03 Cambria Pharmaceuticals, Inc. Pyrimidine-2,4,6-triones for use in the treatment of amyotrophic lateral sclerosis
ME01858B (me) 2009-07-17 2014-12-20 Japan Tobacco Inc Jedinjenje triazolopiridina i njegovo dejstvo kao inhibitora prolil hidroksilaze i induktora proizvodnje eritropoetina
TWI500623B (zh) * 2009-10-13 2015-09-21 Torrent Pharmaceuticals Ltd 新穎稠合噻唑及噁唑嘧啶酮
WO2011049126A1 (ja) 2009-10-21 2011-04-28 第一三共株式会社 ５－ヒドロキシピリミジン－４－カルボキサミド誘導体
KR101483831B1 (ko) 2009-11-06 2015-01-21 에르피오 세러퓨틱스 인코포레이티드 대장염 치료용 조성물 및 방법
AU2011289230B2 (en) 2010-08-13 2014-09-04 Janssen Pharmaceutica Nv 4 - aminoquinazolin- 2 - yl - 1 - pyrrazole - 4 - carboxylic acid compounds as prolyl hydroxylase inhibitors
US8921389B2 (en) 2011-02-02 2014-12-30 Fibrogen, Inc. Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase
GB201102659D0 (en) 2011-02-15 2011-03-30 Isis Innovation Assay
NO2686520T3 (no) 2011-06-06 2018-03-17
KR101652606B1 (ko) 2011-06-06 2016-08-30 아케비아 테라퓨틱스 인코포레이티드 암 치료 방법으로서 저산소증 유도 인자-2 알파를 안정화시키기 위한 화합물 및 조성물
GB201113101D0 (en) 2011-07-28 2011-09-14 Isis Innovation Assay
EP2758058B1 (en) 2011-09-23 2017-04-26 Merck Sharp & Dohme Corp. Substituted pyrimidines
WO2013040789A1 (en) * 2011-09-23 2013-03-28 Merck Sharp & Dohme Corp. Substituted pyrimidines
US9079930B2 (en) 2011-09-23 2015-07-14 Merck Sharp & Dohme Corp. Substituted pyrimidines
WO2013040790A1 (en) * 2011-09-23 2013-03-28 Merck Sharp & Dohme Corp. Substituted pyrimidines
CN102432549B (zh) * 2011-09-28 2014-09-03 南通市华峰化工有限责任公司 一种抑制血管生成、肿瘤发生和增殖疾病的药物中间体1,3-二环己基巴比妥酸的制备方法
ES2574262T3 (es) 2011-10-25 2016-06-16 Janssen Pharmaceutica, N.V. Formulaciones de sal de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico
WO2013070908A1 (en) * 2011-11-09 2013-05-16 Fibrogen, Inc. Therapeutic method
UA112897C2 (uk) * 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань
US9422240B2 (en) 2012-07-30 2016-08-23 Taisho Pharmaceutical Co., Ltd Partially saturated nitrogen-containing heterocyclic compound
CN103146720B (zh) * 2013-03-01 2014-12-03 河北博伦特药业有限公司 一种具有高转化率的反式-4-羟基-l-脯氨酸羟化酶改造基因及其应用
SG10201910773VA (en) 2013-06-13 2020-01-30 Akebia Therapeutics Inc Compositions and methods for treating anemia
JP2016536362A (ja) * 2013-11-08 2016-11-24 バイエル ファーマ アクチエンゲゼルシャフト 置換されているウラシル類及びそれらの使用
WO2015067651A1 (de) 2013-11-08 2015-05-14 Bayer Pharma Aktiengesellschaft Substituierte uracile als chymase inhibitoren
TWI665190B (zh) 2013-11-15 2019-07-11 阿克比治療有限公司 ｛［５－（３－氯苯基）－３－羥基吡啶－２－羰基］胺基｝乙酸之固體型式，其組合物及用途
JP5975122B2 (ja) * 2014-01-29 2016-08-23 大正製薬株式会社 ［（４−ヒドロキシ−２−オキソ−１，２，５，６−テトラヒドロ−３−ピリジニル）カルボニル］グリシン化合物の結晶形及びそれらの製造方法
WO2015126860A1 (en) * 2014-02-19 2015-08-27 Aerpio Therapeutics, Inc. Process for preparing n-benzyl-3-hydroxy-4-substituted-pyridin-2-(1h)-ones
CN104151254A (zh) * 2014-07-25 2014-11-19 南通市华峰化工有限责任公司 一种制备1，3-双环己基巴比妥酸的方法
AU2015311333B2 (en) 2014-09-02 2017-11-16 Sunshine Lake Pharma Co., Ltd. Quinolinone compound and use thereof
WO2016054806A1 (en) * 2014-10-10 2016-04-14 Merck Sharp & Dohme Corp. Substittued pyridine inhibitors of hif prolyl hydroxylase
WO2016054805A1 (en) * 2014-10-10 2016-04-14 Merck Sharp & Dohme Corp. Substituted pyrimidines as inhibitors of hif prolyl hydroxylase
JP2018039733A (ja) * 2014-12-22 2018-03-15 株式会社富士薬品 新規複素環誘導体
CA2974691A1 (en) 2015-01-23 2016-07-28 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
CN106146395B (zh) 2015-03-27 2019-01-01 沈阳三生制药有限责任公司 3-羟基吡啶化合物、其制备方法及其制药用途
JP6929785B2 (ja) 2015-04-01 2021-09-01 アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 貧血治療のための組成物及び方法
US10401548B2 (en) * 2015-09-24 2019-09-03 Intel Corporation Integrated antenna with display uniformity
MX2018004518A (es) 2015-10-14 2018-09-18 X Therma Inc Composiciones y metodos para reducir la formacion de cristales de hielo.
JP6325139B2 (ja) * 2016-03-02 2018-05-16 ネルファルマ・エッセ・エッルレ・エッレ カルムスチンの安全で効率的な製造方法
WO2018205928A1 (zh) 2017-05-09 2018-11-15 杭州安道药业有限公司 吲哚嗪衍生物及其在医药上的应用
CN108623528B (zh) * 2017-05-26 2020-07-07 深圳市塔吉瑞生物医药有限公司 一种取代的嘧啶三酮化合物及包含该化合物的组合物及其用途
AU2018330994A1 (en) 2017-09-15 2020-04-16 GlaxoSmithKline Intellectual Property (No. 2) Limited, England Crystalline forms of gsk1278863, preparation method and pharmaceutical use thereof
CN112088155A (zh) 2018-05-09 2020-12-15 阿克比治疗有限公司 用于制备2-[[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基]乙酸的方法
CN109134356A (zh) * 2018-06-18 2019-01-04 苏州盖德精细材料有限公司 一种中间体2-氨基吡啶-4-甲醇的制备方法
WO2020102302A1 (en) 2018-11-15 2020-05-22 Teva Pharmaceuticals International Gmbh Solid state forms of daprodustat and process for preparation thereof
CN113811530B (zh) * 2019-07-03 2022-07-19 南京明德新药研发有限公司 作为糜酶抑制剂的嘧啶酮类化合物及其应用
CN112752577B (zh) * 2019-08-20 2023-07-07 深圳仁泰医药科技有限公司 Daprodustat的晶型及其制备方法和用途
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
EP4138825A1 (en) 2020-04-20 2023-03-01 Akebia Therapeutics Inc. Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer
US20230225977A1 (en) 2020-06-19 2023-07-20 Glaxosmithkline Intellectual Property (No.2) Limited Formulation comprising daprodustat
CN114671878B (zh) * 2020-12-25 2023-08-04 广东东阳光药业有限公司 取代的含氮双环化合物及其用途
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
WO2022179967A1 (en) 2021-02-23 2022-09-01 Glaxosmithkline Intellectual Property (No.2) Limited Vadadustat for treating covid-19 in a hospitalized subject
CN117999069A (zh) 2021-05-27 2024-05-07 凯克斯生物制药公司 柠檬酸铁的儿科调配物
WO2022263899A1 (en) 2021-06-18 2022-12-22 Glaxosmithkline Intellectual Property (No.2) Limited Novel manufacturing method of daprodustat and precursors thereof
IT202200008693A1 (it) * 2022-04-29 2023-10-29 Dipharma Francis Srl Metodo per la preparazione e la purificazione di un agente per il trattamento dell'anemia
IT202100020609A1 (it) * 2021-07-30 2023-01-30 Dipharma Francis Srl Metodo di preparazione di agente adatto per il trattamento dell'anemia
WO2023006986A1 (en) * 2021-07-30 2023-02-02 Dipharma Francis S.R.L. Method for preparing and purifying an agent suitable for treating anemia
IT202100020591A1 (it) * 2021-07-30 2023-01-30 Dipharma Francis Srl Preparazione di un intermedio di un agente per il trattamento dell'anemia
WO2024022998A1 (en) 2022-07-26 2024-02-01 Inke, S.A. Process for preparing daprodustat and cocrystals thereof
GB202211231D0 (en) 2022-08-02 2022-09-14 Glaxosmithkline Ip No 2 Ltd Novel formulation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658933A (en) * 1993-11-02 1997-08-19 Hoechst Aktiengesellschaft Substituted heterocyclic carboxamide esters, their preparation and their use as pharmaceuticals
WO2004108681A1 (en) * 2003-06-06 2004-12-16 Fibrogen, Inc. Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE118208T1 (de) 1989-10-16 1995-02-15 Chiroscience Ltd Chirale azabicycloheptanone und verfahren zu ihrer herstellung.
AU5316900A (en) 1999-06-03 2000-12-28 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk)
WO2003024955A2 (en) 2001-09-18 2003-03-27 Sunesis Pharmaceuticals, Inc. Small molecule inhibitors of caspases
EP2298301B2 (en) * 2001-12-06 2022-11-16 Fibrogen, Inc. Medicaments for treating anemia associated with kidney disease
US7180893B1 (en) 2002-03-22 2007-02-20 Juniper Networks, Inc. Parallel layer 2 and layer 3 processing components in a network router
JP2006500351A (ja) * 2002-08-13 2006-01-05 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテアーゼ−１３阻害剤としてのピリミジン−２，４−ジオン誘導体
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
US7790734B2 (en) 2003-09-08 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CN102134231B (zh) 2004-03-15 2020-08-04 武田药品工业株式会社 二肽基肽酶抑制剂
JP2007277096A (ja) 2004-07-15 2007-10-25 Astellas Pharma Inc フェネチルニコチンアミド誘導体含有医薬
US7718624B2 (en) 2004-09-01 2010-05-18 Sitkovsky Michail V Modulation of immune response and inflammation by targeting hypoxia inducible factors
CN101849943A (zh) 2005-06-06 2010-10-06 菲布罗根公司 使用HIFα稳定剂的改进的贫血治疗
CA2626549A1 (en) 2005-10-21 2007-04-26 University Of Alabama At Birmingham Small molecule inhibitors of hiv-1 capsid assembly
US7713986B2 (en) 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
US20070293575A1 (en) 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
PE20080209A1 (es) * 2006-06-23 2008-05-15 Smithkline Beecham Corp Derivados de glicina como inhibidores de prolil hidroxilasa
AR061571A1 (es) 2006-06-23 2008-09-03 Smithkline Beecham Corp Compuesto sal del acido toluenosulfonico de 4-{[6-cloro-3-({[(2- cloro-3-fluorofenil) amino]carbonil} amino)- 2- hidroxifenil]sulfonil] -1- piperazinacarbxilato de 1.1-dimetiletilo, composicion farmaceutica que lo comprende su uso para la fabricacion de un medicamento combinacion farmaceutica con un
US20090011051A1 (en) 2006-09-28 2009-01-08 Roth Mark B Methods, Compositions and Articles of Manufacture for HIF Modulating Compounds
WO2008073292A2 (en) 2006-12-08 2008-06-19 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Method for protecting renal tubular epithelial cells from radiocontrast nephro parhy (rcn)
CL2008000065A1 (es) * 2007-01-12 2008-09-22 Smithkline Beecham Corp Compuestos derivados de glicina n-sustituida, inhibidores de hif prolil hidroxilasas; su proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anemia.
AU2018330994A1 (en) 2017-09-15 2020-04-16 GlaxoSmithKline Intellectual Property (No. 2) Limited, England Crystalline forms of gsk1278863, preparation method and pharmaceutical use thereof
WO2020102302A1 (en) 2018-11-15 2020-05-22 Teva Pharmaceuticals International Gmbh Solid state forms of daprodustat and process for preparation thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658933A (en) * 1993-11-02 1997-08-19 Hoechst Aktiengesellschaft Substituted heterocyclic carboxamide esters, their preparation and their use as pharmaceuticals
WO2004108681A1 (en) * 2003-06-06 2004-12-16 Fibrogen, Inc. Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MCDONOUGH MICHAEL ET AL "Cellular oxygen sensing: Crystal structure of hypoxia-inducible factor prolyl hydroxylase (PHD2)", PNAS, 2006, vol.103, nr. 26, s. 9814-9819, Dated: 01.01.0001 *
SILVERBERG DONALD S. ET AL "The Use of SUbcutaneous Erythopoietin and Intravenous Iron for the Treatment of the Anemia of Severe, Resistant Congestive Heart FAilure Improves Cardiac and Renal Function and Functional Cardia Class, and Markedly Reduces Hospitalizations", Journal of the American College of Cardiology, 2000, vol. 35, nr. 7,s. 1737-1744, ISSN 0735-1097/00/$20.00, Dated: 01.01.0001 *

Also Published As

Publication number Publication date
CA2655491A1 (en) 2007-12-27
UA100225C2 (uk) 2012-12-10
JO2934B1 (en) 2015-09-15
US20200157055A1 (en) 2020-05-21
CN101505752B (zh) 2012-12-05
MY149861A (en) 2013-10-31
SG174775A1 (en) 2011-10-28
EP2037922A4 (en) 2012-08-22
JP5203361B2 (ja) 2013-06-05
WO2007150011A2 (en) 2007-12-27
US8324208B2 (en) 2012-12-04
WO2007150011A8 (en) 2008-07-10
BRPI0713446B1 (pt) 2019-10-29
PT2037922E (pt) 2014-04-14
BRPI0713446B8 (pt) 2021-05-25
US8815884B2 (en) 2014-08-26
KR20090030321A (ko) 2009-03-24
US20140024666A1 (en) 2014-01-23
EP2037922B1 (en) 2014-01-22
US20230227414A1 (en) 2023-07-20
HK1130671A1 (en) 2010-01-08
MX2009000165A (es) 2009-01-23
EA018220B1 (ru) 2013-06-28
EP2037922A2 (en) 2009-03-25
PL2037922T3 (pl) 2014-06-30
EP2037922B9 (en) 2017-08-23
US10035779B2 (en) 2018-07-31
IL196070A0 (en) 2009-09-01
US11643397B2 (en) 2023-05-09
US20130072487A1 (en) 2013-03-21
DK2037922T3 (en) 2014-03-24
US20210347740A1 (en) 2021-11-11
NO342019B1 (no) 2018-03-12
NZ573698A (en) 2012-02-24
TWI394747B (zh) 2013-05-01
AR061570A1 (es) 2008-09-03
CA2655491C (en) 2016-09-06
ES2453100T3 (es) 2014-04-04
US20160297772A1 (en) 2016-10-13
AU2007260837B2 (en) 2013-07-04
US20150315157A1 (en) 2015-11-05
KR101411816B1 (ko) 2014-06-24
HRP20140306T1 (hr) 2014-05-09
AU2007260837A1 (en) 2007-12-27
BRPI0713446A2 (pt) 2012-03-06
SI2037922T1 (sl) 2014-04-30
US10336711B2 (en) 2019-07-02
US8557834B2 (en) 2013-10-15
JP2009541351A (ja) 2009-11-26
US20180305323A1 (en) 2018-10-25
EA200970050A1 (ru) 2009-06-30
MA30526B1 (fr) 2009-06-01
PE20080209A1 (es) 2008-05-15
WO2007150011A3 (en) 2008-03-27
ZA200810602B (en) 2010-10-27
CN101505752A (zh) 2009-08-12
US20140336383A1 (en) 2014-11-13
TW200815364A (en) 2008-04-01
CR10534A (es) 2009-03-20
US20100113444A1 (en) 2010-05-06
IL196070A (en) 2015-05-31

Similar Documents

Publication Publication Date Title
NO20090202L (no) Prolylhydroksylaseinhibitorer
MX2009007548A (es) Derivados de glicina n-sustituidos: inhibidores de hidroxilasa.
WO2009073497A3 (en) Prolyl hydroxylase inhibitors
EA201100311A1 (ru) Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы
WO2007103905A3 (en) Prolyl hydroxylase inhibitors
WO2007136990A3 (en) Prolyl hydroxylase inhibitors
NO20083214L (no) Pyrimidinylarylurea-derivater som omdannes til FGF-inhibitorer
TN2009000128A1 (en) Dihydropyridine derivatives useful as protein kinase inhibitors
NO20070529L (no) Kinazolindionderivater som parp-inhibitorer
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
NO20090628L (no) Pyridizinon derivativater
WO2010022307A3 (en) Prolyl hydroxylase inhibitors
NO20073859L (no) Pyrrolopyrazoler, potente kinaseinhibitorer
HRP20050533A2 (en) Aminoindazole derivatives and use thereof as kinase inhibitors
EA201190158A1 (ru) Производные бензофуранила для применения в качестве ингибиторов глюкокиназы
NO20063449L (no) Substituerte heterocykler og deres anvendelse
NO20070555L (no) Kinazolinonderivater som parp-inhibitorer
EA201000920A1 (ru) Ингибиторы пролилгидроксилазы
MX2010009752A (es) Compuestos de oxadiazoantraceno para el tratamiento de diabetes.
NO20092711L (no) Metoder for anvendelse av cyclopaminanaloger
NO20082135L (no) HIV integrase inhibitorer
NO20091553L (no) Fenylderivater og deres anvendelse som immunmodulatorer
WO2007079199A3 (en) Substituted bis-amide metalloprotease inhibitors
NO20064344L (no) Caspaseinhibitorer og anvendelser derav
MX2012002542A (es) Compuestos y composiciones como inhibidores de cinasa de proteina.

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: GLAXOSMITHKLINE LLC, US